Maria 01, Building 5
Lapinlahdenkatu 16, 00180 Helsinki
Making history? email@example.com
Press inquiries: firstname.lastname@example.org
Neuro Event Labs is revolutionizing epilepsy treatment with their AI-powered diagnostics product Nelli™, which brings notable cost savings and improved efficiency to a field of medicine affecting over 65 million people worldwide. Currently, 30% of diagnosed epilepsy cases are later disproved by new methods, and one-third of epilepsy patients continue to have seizures regardless of treatment.
Neuro Event Labs has developed an AI-powered epilepsy diagnostic, which is based on video and audio recordings that can be collected from either the patient’s home or in hospital. Nelli™ is CE-marked and has been launched for regular clinical use at 20 leading European hospitals, and used in collaboration with hospitals in the US.
With healthcare systems around the world currently under stress, it’s all the more important that we develop more solutions for at-home care and diagnosis
Kaapo Annala CEO at Neuro Event Labs.
Neuro Event Labs Co-founder Jukka Peltola, MD and professor in neurology, was frustrated in the current epilepsy treatment methods: epilepsy diagnosis were dependent on hospital visits and only 5% of patients were subjected to Video EEG examinations.
He believed that the best way to learn about each patient’s condition is to be present when the seizure occurs, but up until now, there hasn’t been a technology that allows patients to be monitored at home and produces enough reliable data without causing discomfort or disrupting everyday activities. Now, by collecting high-quality data of the seizures from a patient’s home or the hospital, Neuro Event Labs can more efficiently detect and identify the type of seizure the patient suffers from and thus, offer more personalized treatment.
Exceptional combination of product development and medical field. Jukka Peltola is a professor of neurology at the University of Tampere and chief physician at Tampere University Hospital (TAYS). The CEO Kaapala Annala, is a former Director at Nokia and Microsoft.
Nelli™ is CE-marked and has been launched for regular clinical use at 30 leading European hospitals, and used in collaboration with hospitals in the US.
Nelli® has received a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The system is designed to automate the identification of seizure events using video, audio and sophisticated software algorithms using artificial intelligence (AI). This is the first Breakthrough Device designation for a seizure diagnostic monitoring system. Read more here.